Blog: DECIPHERA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – Marketscreener.com

Item 7.01 Regulation FD Disclosure.

On September 10, 2022, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a
press release announcing the presentation of initial clinical study results from
the ongoing single agent dose escalation portion of the Company’s Phase 1 study
of DCC-3116, the Company’s investigational inhibitor of ULK1/2, in patients with
advanced or metastatic tumors with a mutant RAS or RAF gene, as an oral
presentation at the European Society for Medical Oncology (ESMO) Congress 2022.
A copy of the press release is being furnished as Exhibit 99.1 to this Current
Report on Form 8-K. A copy of the DCC-3116 presentation at the ESMO Congress
2022 is posted on the Investors and News portion of the Company’s website
(www.deciphera.com) under “Events and Presentations”.

On September 11, 2022, the Company issued a press release announcing the
presentation of new clinical study results from the Phase 1 and Phase 2 portions
of the Company’s ongoing study of vimseltinib, the Company’s investigational
inhibitor of CSF1R, in patients with tenosynovial giant cell tumor not amenable
to surgery, as two separate posters at the ESMO Congress 2022. A copy of the
press release is being furnished as Exhibit 99.2 to this Current Report on Form
8-K. Copies of the Phase 1 and Phase 2 posters from the ESMO Congress 2022 are
posted on the Investors and News portion of the Company’s website
(www.deciphera.com) under “Events and Presentations”.

The information in this Current Report on Form 8-K (including Exhibits 99.1 and
99.2 attached hereto) is intended to be furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1      Press Release issued by Deciphera Pharmaceuticals, Inc. on September 10,
        2022

99.2      Press Release issued by Deciphera Pharmaceuticals, Inc. on September 11,
        2022

104     Cover Page Interactive Data File (embedded within the Inline XBRL
        document)

——————————————————————————–

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s